Ticker Details
Innoviva, Inc. Innoviva Inc is a biopharmaceutical company that is engaged in the discovery, development and commercialization of small molecule medicines. The firm collaborates with and receives funding from GlaxoSmithKline.
IPO Date:	November 25, 2008
Sector:	Healthcare
Industry:	Pharma
Market Cap:	$1.79B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.20 | 1.44%
Avg Daily Range (30 D):	$0.27 | 1.16%
Avg Daily Range (90 D):	$0.24 | 1.12%

Institutional Daily Volume
Avg Daily Volume:	.64M
Avg Daily Volume (30 D):	.48M
Avg Daily Volume (90 D):	.53M

Trade Size
Avg Trade Size (Sh.):	92
Avg Trade Size (Sh.) (30 D):	39
Avg Trade Size (Sh.) (90 D):	45

Institutional Trades
Total Institutional Trades:	4,521
Avg Institutional Trade:	$1.8M
Avg Institutional Trade (30 D):	$3.01M
Avg Institutional Trade (90 D):	$2.81M
Avg Institutional Trade Volume:	.12M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.89M
Avg Closing Trade (30 D):	$3.96M
Avg Closing Trade (90 D):	$3.8M
Avg Closing Volume:	123.76K

News

Apr 9, 2026 @ 1:55 PM 3 Bargain-Cheap Small Caps Worth a Second Look Source: Chris Markoch

Feb 10, 2026 @ 10:55 AM Tetracyclines Market is Poised to Garner Valuation... Source: Astute Analytica

Jan 8, 2026 @ 3:06 PM Biotech Is Heating Up—These 2 Red-Hot Stock... Source: Nathan Reiff

Aug 7, 2025 @ 3:17 AM Innoviva (INVA) Q2 Sales Jump 64% Source: Na

Dec 16, 2024 @ 6:15 AM Basilea announces agreement with Innoviva Specialt... Source: N/A

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$4.02	$2.37	$4.02
Diluted EPS	$3.3	$1.95	$3.3
Revenue	$411.33M	$114.61M	$411.33M
Gross Profit	$307.67M	$75.67M	$307.67M
Net Income / Loss	$271.17M	$164.15M	$271.17M
Operating Income / Loss	$163.75M	$38.99M	$163.75M
Cost of Revenue	$103.66M	$38.95M	$103.66M
Net Cash Flow	$245.98M	$74.43M	$245.98M
PE Ratio	7.20

Splits
Jun 17, 2013	1:100